Literature DB >> 27410413

Hantavirus cardiopulmonary syndrome successfully treated with high-volume hemofiltration.

Guillermo Bugedo1, Jorge Florez1, Marcela Ferres2, Eric Roessler3, Alejandro Bruhn1.   

Abstract

Hantavirus cardiopulmonary syndrome has a high mortality rate, and early connection to extracorporeal membrane oxygenation has been suggested to improve outcomes. We report the case of a patient with demonstrated Hantavirus cardiopulmonary syndrome and refractory shock who fulfilled the criteria for extracorporeal membrane oxygenation and responded successfully to high volume continuous hemofiltration. The implementation of high volume continuous hemofiltration along with protective ventilation reversed the shock within a few hours and may have prompted recovery. In patients with Hantavirus cardiopulmonary syndrome, a short course of high volume continuous hemofiltration may help differentiate patients who can be treated with conventional intensive care unit management from those who will require more complex therapies, such as extracorporeal membrane oxygenation.

Entities:  

Mesh:

Year:  2016        PMID: 27410413      PMCID: PMC4943057          DOI: 10.5935/0103-507X.20160032

Source DB:  PubMed          Journal:  Rev Bras Ter Intensiva        ISSN: 0103-507X


  17 in total

1.  Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock.

Authors:  P M Honore; J Jamez; M Wauthier; P A Lee; T Dugernier; B Pirenne; G Hanique; J R Matson
Journal:  Crit Care Med       Date:  2000-11       Impact factor: 7.598

Review 2.  Treatment of hantavirus pulmonary syndrome.

Authors:  Colleen B Jonsson; Jay Hooper; Gregory Mertz
Journal:  Antiviral Res       Date:  2007-11-21       Impact factor: 5.970

Review 3.  Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation.

Authors:  M R Crowley; R W Katz; R Kessler; S Q Simpson; H Levy; G W Hallin; J Cappon; J B Krahling; J Wernly
Journal:  Crit Care Med       Date:  1998-02       Impact factor: 7.598

4.  [Hantavirus pulmonary syndrome with multiple organ dysfunctions: case report].

Authors:  Marcelo Spegiorin Moreno; Ricardo Condi Castelão; Rodrigo Teno Castilho Braga; Suzana Margareth Lobo
Journal:  Rev Bras Ter Intensiva       Date:  2007-12

5.  A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus.

Authors:  Pablo A Vial; Francisca Valdivieso; Mario Calvo; M Luisa Rioseco; Raul Riquelme; Andres Araneda; Vinko Tomicic; Jerónimo Graf; Laura Paredes; Matias Florenzano; Teresa Bidart; Analia Cuiza; Claudia Marco; Brian Hjelle; Chunyan Ye; Diane Hanfelt-Goade; Cecilia Vial; Juan C Rivera; Iris Delgado; Gregory J Mertz
Journal:  Antivir Ther       Date:  2014-10-15

6.  High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial.

Authors:  Olivier Joannes-Boyau; Patrick M Honoré; Paul Perez; Sean M Bagshaw; Hubert Grand; Jean-Luc Canivet; Antoine Dewitte; Claire Flamens; Wilfried Pujol; Anne-Sophie Grandoulier; Catherine Fleureau; Rita Jacobs; Christophe Broux; Hervé Floch; Olivier Branchard; Stephane Franck; Hadrien Rozé; Vincent Collin; Willem Boer; Joachim Calderon; Bernard Gauche; Herbert D Spapen; Gérard Janvier; Alexandre Ouattara
Journal:  Intensive Care Med       Date:  2013-06-06       Impact factor: 17.440

7.  Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America.

Authors:  Gregory J Mertz; Lil Miedzinski; Diane Goade; Andrew T Pavia; Brian Hjelle; Christine O Hansbarger; Howard Levy; Frederick T Koster; Kenneth Baum; Adeline Lindemulder; Wenquan Wang; Laura Riser; Humberto Fernandez; Richard J Whitley
Journal:  Clin Infect Dis       Date:  2004-10-11       Impact factor: 9.079

8.  An evidence-based resuscitation algorithm applied from the emergency room to the ICU improves survival of severe septic shock.

Authors:  R Castro; T Regueira; M L Aguirre; O P Llanos; A Bruhn; G Bugedo; A Dougnac; L Castillo; M Andresen; G Hernández
Journal:  Minerva Anestesiol       Date:  2008-03-21       Impact factor: 3.051

9.  High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial.

Authors:  Pablo A Vial; Francisca Valdivieso; Marcela Ferres; Raul Riquelme; M Luisa Rioseco; Mario Calvo; Constanza Castillo; Ricardo Díaz; Luis Scholz; Analia Cuiza; Edith Belmar; Carla Hernandez; Jessica Martinez; Sang-Joon Lee; Gregory J Mertz
Journal:  Clin Infect Dis       Date:  2013-06-19       Impact factor: 9.079

10.  Corticosteroids combined with continuous veno-venous hemodiafiltration for treatment of hantavirus pulmonary syndrome caused by Puumala virus infection.

Authors:  E Seitsonen; M Hynninen; E Kolho; H Kallio-Kokko; V Pettilä
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

View more
  1 in total

1.  Targeted high volume hemofiltration could avoid extracorporeal membrane oxygenation in some patients with severe Hantavirus cardiopulmonary syndrome.

Authors:  René López; Rodrigo Pérez-Araos; Álvaro Salazar; Mauricio Espinoza; Cecilia Vial; Analia Cuiza; Pablo A Vial; Jerónimo Graf
Journal:  J Med Virol       Date:  2021-03-23       Impact factor: 2.327

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.